Cell Therapeutics.

Our mission is to develop novel therapies to target against atherosclerosis (arterial blockages) and its consequences – heart attack and stroke.

Our treatment mission is to bypass arterial blockages by stimulating new blood vessel growth, to restore blood flow to affected regions.

Our central purpose is to develop therapies to treat atherosclerosis and promote cardiovascular regeneration. Such work will be performed in collaboration with the Clinical, Translational, Inflammation and Immunobiology Groups within the HRI, drawing upon their expertise in these areas of research.

What impact will this research have?

By reducing atherosclerotic plaque build up, we aim to reduce death and disability associated with heart and lower limb arterial disease. Also, by stimulating the growth of new blood vessels in patients with arterial blockages, our work aims to reduce symptoms associated with insufficient blood supply to the heart and legs.

Associate Professor Sanjay Patel
Research group led by:
Research covers areas of:
What’s new in the lab?

Greg and Jo's story

Every day, 23 Australians die from a heart attack. Every year, roughly 55,000 suffer a life-threatening cardiovascular emergency. Like so many, Greg Bridgman never thought it would happen to him.

Current team update

Zoe Clayton is currently completing her PhD, investigating the ability of certain novel cell types to promote new blood vessel growth in cardiovascular disease settings.

Jun 07, 2015

Help fund vital research into heart disease

Select your donation details
You can choose between donating once or monthly.
Please enter or select your donation amount.
Invest in a future free from cardiovascular disease.
Your donation will allow great science to flourish.
All donations are tax deductible.